Elranatamab: Mechanism of Action, Clinical, and Translational Science [0.03%]
Elranatamab：作用机制、临床和转化科学
Mohamed Elmeliegy,Andrea Viqueira,Erik Vandendries et al.
Mohamed Elmeliegy et al.
Elranatamab (ELREXFIO) is a humanized bispecific antibody approved for patients with relapsed/refractory multiple myeloma (RRMM). Elranatamab engages CD3 on T cells and B-cell maturation antigen (BCMA) on myeloma cells to induce T cell-medi...
Modulation of Inflammatory Indices by Omega-3 Fatty Acids Supplementation in Hemodialysis: A Clinical Trial Approach [0.03%]
以临床试验方法探讨ω-3脂肪酸补充对透析患者发炎指数之影响
Hanieh Shafaei Kachaei,Khadijeh Abbasi Mobarakrh,Fatemeh Azaryan et al.
Hanieh Shafaei Kachaei et al.
Chronic kidney disease (CKD) is closely associated with systemic inflammation. This randomized controlled trial aimed to evaluate the effects of omega-3 fatty acids supplementation on inflammatory markers in patients with CKD undergoing hem...
Randomized Controlled Trial
Clinical and translational science. 2026 May;19(5):e70531. DOI:10.1111/cts.70531 2026
Jean-Jacques Parienti
Jean-Jacques Parienti
Advancing IBD Management: A Literature Review on the Role of Non-Invasive Blood-Based Biomarkers in Predicting and Assessing Pharmacodynamic Response to Treatment [0.03%]
炎症性肠病管理进展：文献综述——非侵入性血基生物标志物在预测和评估药物治疗动态反应中的作用
Mohamed Hassanein,Li Xi,Rathi D Ryan et al.
Mohamed Hassanein et al.
Reliable biomarkers that enable noninvasive, longitudinal assessment of disease activity and therapeutic response remain a major unmet need in inflammatory bowel disease (IBD). While colonic biopsies are the gold standard for evaluating muc...
Advancing Pharmacoequity in Low- and Middle-Income Countries via Model Informed Drug Development [0.03%]
通过模型引导药物研发在中低收入国家推进药学公平性
Henry Enzama,Francis Williams Ojara,Ian S Haworth et al.
Henry Enzama et al.
Across low- and middle-income countries (LMICs) inequities in access to safe, effective medicines persist due to limited regulatory capacity, inadequate financing, and insufficient local data. Regulatory authorities are engaging with model-...
Methodological Considerations for AI-Powered Chatbots in Oral Cancer Awareness: Stakeholder Diversity, Instrument Transparency, and Safety Auditing [0.03%]
人工智能驱动的口腔癌意识聊天机器人的方法论考量：利益相关者多样性、仪器透明度和安全审计
Carlos Fernando Mourão,Luiz Eduardo Juliasse,Rodrigo Dos Santos Pereira
Carlos Fernando Mourão
Nomlabofusp Treatment Produces Frataxin Levels That Correlate Across Peripheral Tissues: Preclinical and Clinical Support for Surrogate Tissue Sampling [0.03%]
Nomlabofusp治疗产生的线性铁蛋白水平与外周组织相关：支持替代组织采样的临床前和临床证据
Flavia De Toni,Mohamed Hamdani,Chintan Patadia et al.
Flavia De Toni et al.
Nomlabofusp is a recombinant, cell-penetrating human frataxin (hFXN) fusion protein in development for the treatment of Friedreich's ataxia (FRDA). This study evaluated whether nomlabofusp-derived hFXN concentrations covary across accessibl...
Exploratory Evaluation of Solanidine as an Endogenous Marker for CYP2D6-Mediated Drug-Drug-Gene Interactions of Venlafaxine in Koreans [0.03%]
ソラナidine的探索性评价及其作为CYP2D6介导的文拉法辛药物-基因相互作用内源性标志物在韩国人中的应用研究
Sungyeun Bae,Ga-Yeong Lee,Eunsol Yang et al.
Sungyeun Bae et al.
CYP2D6-mediated drug-drug-gene interactions (DDGIs) are known to influence the pharmacokinetics of venlafaxine and its metabolism to O-desmethylvenlafaxine. Solanidine and 3,4-seco-solanidine-3,4-dioic acid (SSDA) have recently been investi...
Understanding Motivation to Participate in Clinical Trials: Insights to Diversify Clinical Research Using Health Information National Trends Survey [0.03%]
临床试验参与动机的理解：利用卫生信息国家趋势调查促进临床研究的多样性
Rifath Ara Alam Barsha,Shervin Assari,Samuel Byiringiro et al.
Rifath Ara Alam Barsha et al.
Motivation plays a central role in driving individuals to participate in clinical trials, and understanding its multifaceted nature is essential for improving trial diversity. This study aimed to (1) identify the different dimensions of mot...
Cancer Biomarker Test Utilization and Reimbursement in Australia: A National Analysis of Medicare Data [0.03%]
澳大利亚癌症生物标志物检测的利用和报销：Medicare数据的全国分析
Leping Kong,Christine Y Lu
Leping Kong
Biomarker testing plays a critical role in precision oncology by guiding targeted therapy selection. In Australia, public reimbursement for somatic tumor biomarker tests has expanded over the past decade, yet national data on utilization pa...